NCT05338931

Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

An Open-label, Single-arm, Multi-center, Phase I/II Study to Evaluate the Safety, Tolerability, and Efficacy of AT101 (Anti-CD19 Chimeric Antigen Receptor T Cell) in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

• Status: Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 82 (estimated)
• Sponsor: AbClon · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

Determine MTD based on the safety and tolerability of AT101 and the RP2D for patients with recurrent or non-reactive B-cell NHL.

Detailed description

Determine the maximum tolerant dose (MTD) based on the safety and tolerability of AT101 and the recommended dose 2 dose (RP2D) in phase 2 trials for patients with recurrent or non-reactive B cell non-Hodgkin lymphoma (B-cell NHL).

Conditions

• B-cell Non Hodgkin Lymphoma

Interventions

Type	Name	Description
DRUG	AT101(Anti-CD19 Chimeric Antigen Receptor T cell)	Anti-CD19 Chimeric Antigen Receptor T cell

Timeline

• Start date: 2022-03-15
• Primary completion: 2030-03-15
• Completion: 2030-09-15
• First posted: 2022-04-21
• Last updated: 2022-05-26

Locations

1 site across 1 country: South Korea